This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


REGiMMUNE Co., Ltd.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2014/9/18
Profile

Delegates :
YASUYUKI ISHII


Incorporated :
March  3 , 2006

Paid in Capital :
535 Million yen  

Employees :
8 人

Address :
Kodenma-chou Fine building 7F 14-9 Kodenma-chou, Nihonbashi, Chuou TOKYO
〒103-0001

TEL/FAX :
+81-3-5614-0007 / +81-3-5614-0008

URL:
http://www.regimmune.com

Attachment :
REGiMMUNE_Mar2014E.pdf [ 6.3MiB ]

Mission/Background :
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company’s proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells.

Technology & Business
Using reVax technology, REGiMMUNE is developing RGI-2001, which may be the first drug in the class of Treg-inducing agents. The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-1000 series for allergy and its RGI-3100 series for type 1 diabetes. Additionally REGiMMUNE is developing products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease.
Products & Service
Products & Service Name
Stage
Outline
Milestone
RGI-2001
Phase2
Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT
The company is seeking pharmaceutical partnership opportunities for its products worldwide, exclusive of Japan.
RGI-3300
Discovery
Celiac disease
Seeking pharmaceutical collaborators












Highlights
The potential of a novel approach using RGI-2001 and suboptimal dosage of antibody for that blocks CD40:CD40L signaling as a powerful method to generate mixed chimerism in various animal models of bone transplantation was proved (Toshihito Hirai, Yasuyuki Ishii and et al. A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Co-stimulatory Blockade. Am J Transplant 2014 Mar;14(3):554-67.)
Hot news
REGiMMUNE Co is going to seek pharmaceutical partnership opportunities for RGI-2001 in BIOJAPAN 2014.
Alliance strategy
The company is seeking pharmaceutical partnership opportunities for RGi-2001 worldwide, exclusive of Japan.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.